Biomerica's inFoods IBS Test Gets $300 Medicare Payment Rate from CMS

Biomerica, a global provider of diagnostic solutions, has announced that the Centers for Medicare & Medicaid Services (CMS) has set a national Medicare payment rate of $300 for its inFoods IBS test under the Clinical Laboratory Fee Schedule (CLFS). The rate applies to claims approved and paid by Medicare with dates of service on or after January 1, 2026. This milestone is significant as Medicare is the single largest payer for healthcare in the US, covering approximately 21% of total healthcare expenditure. Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods IBS.